Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Monitoring Early Response to Anti-Angiogenic Therapy: Diffusion-Weighted Magnetic Resonance Imaging and Volume Measurements in Colon Carcinoma Xenografts

  • Moritz Jörg Schneider ,

    Affiliation Josef Lissner Laboratory for Biomedical Imaging, Institute for Clinical Radiology, Ludwig-Maximilians-University Hospital Munich, Munich, Germany

  • Clemens Christian Cyran,

    Affiliation Laboratory for Experimental Radiology, Institute for Clinical Radiology, Ludwig-Maximilians-University Hospital Munich, Munich, Germany

  • Konstantin Nikolaou,

    Affiliations Laboratory for Experimental Radiology, Institute for Clinical Radiology, Ludwig-Maximilians-University Hospital Munich, Munich, Germany, Department of Diagnostic and Interventional Radiology, University Hospital Tübingen, Tübingen, Germany

  • Heidrun Hirner,

    Affiliation Laboratory for Experimental Radiology, Institute for Clinical Radiology, Ludwig-Maximilians-University Hospital Munich, Munich, Germany

  • Maximilian F. Reiser,

    Affiliations Josef Lissner Laboratory for Biomedical Imaging, Institute for Clinical Radiology, Ludwig-Maximilians-University Hospital Munich, Munich, Germany, Laboratory for Experimental Radiology, Institute for Clinical Radiology, Ludwig-Maximilians-University Hospital Munich, Munich, Germany

  • Olaf Dietrich

    Affiliation Josef Lissner Laboratory for Biomedical Imaging, Institute for Clinical Radiology, Ludwig-Maximilians-University Hospital Munich, Munich, Germany

Monitoring Early Response to Anti-Angiogenic Therapy: Diffusion-Weighted Magnetic Resonance Imaging and Volume Measurements in Colon Carcinoma Xenografts

  • Moritz Jörg Schneider, 
  • Clemens Christian Cyran, 
  • Konstantin Nikolaou, 
  • Heidrun Hirner, 
  • Maximilian F. Reiser, 
  • Olaf Dietrich



To evaluate the use of diffusion-weighted MRI (DW-MRI) and volume measurements for early monitoring of antiangiogenic therapy in an experimental tumor model.

Materials and Methods

23 athymic nude rats, bearing human colon carcinoma xenografts (HT-29) were examined before and after 6 days of treatment with regorafenib (n = 12) or placebo (n = 11) in a clinical 3-Tesla MRI. For DW-MRI, a single-shot EPI sequence with 9 b-values (10–800 s/mm2) was used. The apparent diffusion coefficient (ADC) was calculated voxelwise and its median value over a region of interest, covering the entire tumor, was defined as the tumor ADC. Tumor volume was determined using T2-weighted images. ADC and volume changes between first and second measurement were evaluated as classifiers by a receiver-operator-characteristic (ROC) analysis individually and combined using Fisher's linear discriminant analysis (FLDA).


All ADCs and volumes are stated as median±standard deviation. Tumor ADC increased significantly in the therapy group (0.76±0.09×10−3 mm2/s to 0.90±0.12×10−3 mm2/s; p<0.001), with significantly higher changes of tumor ADC than in the control group (0.10±0.11×10−3 mm2/s vs. 0.03±0.09×10−3 mm2/s; p = 0.027). Tumor volume increased significantly in both groups (therapy: 347.8±449.1 to 405.3±823.6 mm3; p = 0.034; control: 219.7±79.5 to 443.7±141.5 mm3; p<0.001), however, the therapy group showed significantly reduced tumor growth (33.30±47.30% vs. 96.43±31.66%; p<0.001). Area under the curve and accuracy of the ADC-based ROC analysis were 0.773 and 78.3%; and for the volume change 0.886 and 82.6%. The FLDA approach yielded an AUC of 0.985 and an accuracy of 95.7%.


Regorafenib therapy significantly increased tumor ADC after 6 days of treatment and also significantly reduced tumor growth. However, ROC analyses using each parameter individually revealed a lack of accuracy in discriminating between therapy and control group. The combination of both parameters using FLDA substantially improved diagnostic accuracy, thus highlighting the potential of multi-parameter MRI as an imaging biomarker for non-invasive early tumor therapy monitoring.


Monitoring the response to anti-cancer treatment is an integral part of oncology. With the introduction of novel molecular cancer therapies to clinical routine it has become apparent that conventional, solely morphology-based imaging criteria, such as the Response Evaluation Criteria in Solid Tumors (RECIST) [1], provide limited sensitivity to assess therapy response, particularly during initial treatment [2], [3]. Technical developments in recent years introduced a variety of new functional imaging methods, such as diffusion-weighted MRI (DW-MRI) or perfusion imaging. These new methods complement established morphological information and are also applicable as in-vivo imaging biomarkers of therapy response for monitoring of anti-cancer treatment.

DW-MRI is a method to visualize and quantify the mobility of water molecules in the observed tissue [4], [5]. The thermally driven random motion, the so-called Brownian motion, is influenced by the properties of the surrounding tissue microstructure, e. g. cellular density and cell integrity. While qualitative DW-MRI is already widely used in oncology for the detection of metastases, several recent reviews have highlighted the potential of quantitative DW-MRI, i.e. the measurement of the apparent diffusion coefficient (ADC), to predict and to monitor response to anti-cancer treatment [6][11]. Generally, malignant lesions are known to exhibit lower ADCs compared to healthy tissue and benign lesions, which is mainly a result of the commonly higher cellularity of malignancies [12][17]. On the other hand, studies measuring pre-treatment ADCs have found, that relatively high initial ADCs in malignant lesions were predictive of poor therapy outcome [18][21], while increasing ADCs over the duration of various anti-cancer treatments were associated with therapy response in malignant breast metastases [22], rhabdomyosarcomas [23], prostate carcinoma xenografts [24], colorectal liver metastases [25] and cholangiocarcinomas [26].

The novel oral multi-kinase inhibitor regorafenib exhibits anti-angiogenic and anti-proliferative effects on glioblastoma, breast, and renal cell carcinoma xenografts [27] and is clinically approved for treatment in metastatic colorectal cancer [28]. Pharmacologically, regorafenib belongs to the group of multi tyrosinekinase inhibitors and inhibits multiple membrane-bound and intracellular kinases involved in tumorigenesis, neoangiogenesis and in the preservation of the tumor microenvironment. In vitro, regorafenib has been shown to inhibit the activity of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, FGFR-1, FGFR-2, RET, KIT, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, SAPK2, PTK5 and Abl at concentrations that can be achieved clinically [27].With reported pro-apoptotic effects of regorafenib in colon carcinoma xenografts [29] and studies reporting significant positive correlations between ADCs and the number of apoptotic tumor cells [30], we hypothesized that quantitative ADC measurements would be applicable to sensitively assess the effects of regorafenib in an experimental model of human colon cancer. An anticipated potential limitation of this approach as reliable imaging biomarker is necrotic tumor transformation with progressing tumor growth. Necrotic transformation also leads to augmented water mobility [15] and potentially impairs the specificity of ADC measurements for assessing treatment response. A meaningful combined evaluation of tumor morphology and DW-MRI could reduce the individual limitations of each approach, allowing for non-invasive response monitoring during initial treatment. Such a combination is constituted by Fisher's linear discriminant analysis (FLDA) [31], which has been demonstrated to increase the accuracy to separate between malignant and benign lesions in the vertebral bone marrow by incorporating ADC and T2 relaxation time values compared to using each classifier individually [32].

The purpose of this study was to evaluate quantitative DW-MRI and tumor growth measurements, individually and combined using a discriminant analysis approach, as means of distinguishing between therapy and control group of human colorectal carcinoma in rats under regorafenib or placebo therapy. We hypothesized that the combination of both approaches outperforms each classifier individually and can be used to monitor anti-angiogenic therapy non-invasively.

Materials and Methods

Animal Model

This study was approved by the Government of Upper Bavaria Committee for Animal Research (Gz.55.2-1-54-2532-33-10) and was carried out in accordance with the guidelines of the National Institute of Health for the care and use of laboratory animals. For the experiments twenty-three female athymic rats (7–8 weeks old, Harlan Laboratories Inc., Indianapolis, IN) were used. 2×106 cells of the human colon carcinoma cell line HT-29 (ATCC HTB-38) suspended in a total volume of 0.5 mL as a 1∶1 mixture of phosphate buffered saline pH 7.4 (PBS) and Matrigel (BD Biosciences, San Jose, CA) were injected subcutaneously into the left flanks. Prior to MRI the xenografts were allowed to grow to a reasonable size for imaging of approximately 400 mm3 (assessed by daily caliper measurements in three dimensions (a×b×c×0.5)) and the animals were randomly assigned to either the therapy (n = 12) or the control group (n = 11). After the initial MRI on day 0 the animals and were treated daily for one week with the multi-tyrosine kinase inhibitor, regorafenib (Bayer HealthCare, Leverkusen, Germany), respectively with the placebo. On day 7 a follow-up MRI was performed to assess the effects of regorafenib on tumor growth and the ADC, after which the animals were euthanized via intracardiac injection of potassium chloride.

Tumor Therapy

The therapy group was administered 10 mg/kg body weight of regorafenib daily, formulated as a solution in polypropylene glycol/PEG400/Pluronic F68 (42.5/42.5/15 + 20% Aqua), via gastric gavage, using a dedicated 16-gauge curved buttoned cannula. The control group received volume-equivalent applications of the regorafenib solvent daily.

MR Image Acquisition

Prior to MR imaging, animals were anaesthetized with isoflurane (5% for induction, 2.5% for maintenance, administered in pure oxygen). Scans were conducted on a clinical 3-Tesla whole-body MRI system (MAGNETOM Verio, Siemens Healthcare, Erlangen, Germany) with a small 4-channel flex coil (Siemens Healthcare, Erlangen, Germany).

DW-MRI was performed using a diffusion-weighted single-shot spin-echo sequence with echoplanar imaging (EPI) readout. A modified monopolar diffusion encoding scheme [33] was used to achieve a reduction in TE and therefore an increase in signal intensity. Trace diffusion-weighted images were calculated by averaging images obtained with diffusion gradients in 3 orthogonal directions. A total of 9 diffusion weightings (b-values) were acquired (b = 10; 25; 50; 80; 130; 200; 350; 550; 800 s/mm2) with the parameters listed in Table 1. To assess the tumor volumes, a T2-weighted turbo-spin-echo sequence with a high in-plane resolution of 0.3×0.3 mm2 was used (Table 1).

Image Analysis

Image analysis was performed on a dedicated workstation using our in-house software PMI (Platform for Research in Medical Imaging) [34] written in IDL (ITT Visual Information Systems, Boulder, CO).


Prior to quantitative analysis, the diffusion-weighted images were rigidly registered along the b-value-dimension using a Fourier cross-correlation method to keep bulk-motion from affecting the diffusion coefficients. The ADC of each voxel was calculated by non-linear least-squares fitting of the measured signal intensities from all acquired b-values to the monoexponential diffusion model: S(b)  = S0× exp(− b×ADC), where b is the b-value and S0 the signal intensity at b = 0 (Figure 1).

Figure 1. Voxelwise calculated ADC maps in the subcutaneous colon carcinoma of a therapy animal before and after 6 days of therapy with regorafenib laid over diffusion-weighted images with b = 10 s/mm2.

The ADC maps display a prominent increase, which is also reflected in the median tumor ADC value for this animal: ADCB = 0.762×10−3mm2/s at day 0, ADCF = 1.137×10−3mm2/s at day 7.

Obtaining quantitative parameters from MRI measurements is highly dependent on region of interest (ROI) placement, which often suffers from poor reproducibility. To obtain robust results and to minimize subjective influences on the ROI definition, we defined a 3D volume of interest (VOI) covering the entire tumor on multiple slices of the diffusion-weighted data for each animal and measurement (Figure 2). The median of the ADC distributions inside the VOIs were then taken as the representative tumor ADCs for statistical analysis. The tumor ADCs are denoted ADCB and ADCF for the baseline and follow-up measurements, respectively.

Figure 2. Region of interest (ROI) placement on diffusion-weighted images with b = 10 s/mm2 over 4 example slices to calculate the median tumor ADC.

Total ROI extends over 10 slices for this measurement.

Volume Measurement.

The tumor volumes were determined based on the morphologic T2-weighted images, which allowed for a clear delineation of the subcutaneous xenografts. For each animal and each measurement, a VOI was placed over several slices to cover the entire tumor (Figure 3). The combined volume of all voxels inside each VOI was defined as the tumor volume (the slice gap is 0 mm and therefore did not need to be taken into account) and denoted as VOLB and VOLF for the baseline and follow-up measurements, respectively. To accommodate for varying pre-therapy tumor sizes, tumor growth was assessed in percentages relative to the baseline value rather than absolute growth.

Figure 3. Region of interest (ROI) placement on T2-weighted images over 4 example slices to measure the tumor volume.

Total ROI extends over 22 slices for this measurement.

Statistical Analyses

All statistical analyses were performed using the statistical computing language R [35]. Within each group, median values and standard deviations of the evaluated parameters over all animals were determined. For intragroup comparison between baseline and follow-up parameters, the paired Wilcoxon signed-rank test was used. The comparison of the parameters between the therapy and control group was performed using the non-paired Mann-Whitney U test. The observed changes for both tumor ADCs (ΔADC) and volumes (ΔVOL) from baseline to follow-up were also used for analyses. To evaluate diagnostic performance of either ΔADC or ΔVOL in discriminating therapy from control group, the receiver operating characteristics (ROC) curves were analyzed using the R package pROC [36]. Parameters of interest were the area under the curve (AUC) as well as the optimal threshold and the resulting sensitivity, specificity, and diagnostic accuracy. The statistical significance of the difference between the AUCs was determined using the method as described by DeLong et al. [37] based on generalized U-statistics to generate an estimated covariance matrix.

Additionally, for each group the linear correlation between ΔADC and ΔVOL was determined using Pearson's product-moment correlation. To assess if the combination of both parameters, ΔADC and ΔVOL, increases the ability to distinguish between therapy and control group compared to the individual classifiers, Fisher's linear discriminant analysis [31] was performed using the R package Bioconductor [38], [39]. FLDA is a statistical method used to find a linear combination of given classifiers, in our case ΔADC and ΔVOL, which allows for an optimal separation of a group of classes. The result from the determined linear combination was then again used for statistical comparison between the two groups and as a classifier to perform a ROC curve analysis. For all analyses, p-values of less than 0.05 were considered statistically significant.


Tumor ADC

Median tumor ADCs with standard deviations and the results from the statistical analyses are summarized in Table 2 (see Table S1 for voxelwise calculated ADC distributions and Table S2 for individual tumor ADC values (median of the distributions) for each animal and measurement). A statistically highly significant (p<0.001) difference in tumor ADC between baseline and follow-up measurement was found in the therapy group, where the median increased from ADCB = 0.782(±0.085)×10−3 mm2/s to ADCF = 0.911(±0.121)×10−3 mm2/s. Conversely, no significant alteration was found in the control group (ADCB = 0.740(±0.087)×10−3 mm2/s to ADCF = 0.770 (±0.070)×10−3 mm2/s, p = 0.24). Statistically significant differences between the two groups were found for the follow-up tumor ADCs (p<0.001) as well as for the observed changes in tumor ADCs (therapy: ΔADC = 0.130(±0.110)×10−3 mm2/s; control: ΔADC = 0.030(±0.087)×10−3 mm2/s; p = 0.268; Figure 4a). The ROC curve analysis for ΔADC is illustrated in Figure 5a. The AUC was 0.773 and using an optimal threshold of ΔADC = 0.329×10−3 mm2/s (above = therapy), a sensitivity of 91.7%, a specificity of 63.6%, and a diagnostic accuracy of 78.3% in differentiating between therapy and control group based on ADC changes was obtained (Table 3).

Figure 4. Box plots (first, second, and third quartile, range and outlier) of (a) ΔADC, (b) ΔVOL and (c) the results from the linear combination calculated with Fisher's linear discriminant analysis (FLDA) for each group and the corresponding p-value for the difference between them.

Although significantly different, ΔADC and ΔVOL display distinctive overlaps between the two groups. The result from FLDA demonstrates a marked improvement in the group discrimination with nearly no overlap, resulting in a highly significant difference.

Figure 5. ROC curve analysis using (a) ΔADC, (b) ΔVOL and (c) the result from the linear combination calculated with Fisher's linear discriminant analysis (FLDA) to illustrate performance in differentiating therapy from control group.

The combined approach using FLDA outperforms the use of ΔADC and ΔVOL notably. Optimal sensitivity and specificity for each parameter and the corresponding thresholds are summarized in Table 3. * AUC using ΔADC vs AUC using FLDA: p = 0.035.

Table 2. Median tumor ADCs ± standard deviation for each measurement and group.

Table 3. Results from the ROC curve analysis using ΔADC, ΔVOL, and FLDA.

Tumor Volume

Median tumor volumes with standard deviations and the results from the statistical analyses are summarized in Table 4 (see Table S3 for individual tumor volumes for each animal and measurement). Both groups displayed a statistically significant increase in tumor volume from baseline to follow-up measurements (therapy: p = 0.034; control: p<0.001), however, the observed relative volume increase in the therapy group (ΔVOL = 33.29(±47.30)%) was significantly smaller than in the control group (ΔVOL = 96.43(±31.66)%); p<0.001; Figure 4b). The ROC curve analysis for ΔVOL is illustrated in Figure 5b. The AUC was 0.886 and using an optimal threshold of ΔVOL = 61.35% (below = therapy) a sensitivity of 81.8%, a specificity of 83.3%, and a diagnostic accuracy of 82.6% in differentiating between therapy and control group based on tumor growth was obtained (Table 3). There was no statistically significant difference between the AUC from ΔADC and ΔVOL (p = 0.419). The control group displayed a moderate correlation between ΔADC and ΔVOL (r = 0.65, p = 0.0319, figure 6a, dotted red line), which was not the case for the therapy group (r = 0.05, p = 0.887, Figure 6a, dashed blue line).

Figure 6. Fisher's linear discriminant anaylsis of volume and ADC data.

Panel (a) illustrates thescatterplot of ΔVOL vs. ΔADC for each tumor. The solid grey line represents the optimal threshold determined by the ROC curve analysis; the linear regressions for each group (dashed line for therapy, dotted line for control) are annotated with Pearson's correlation coefficient r and p-value. (b) Results from the FLDA-derived linear combination of ΔADC and ΔVOL (FLDA = 0.0033×ΔVOL[%] - 1.0366×ΔADC[10−3 mm2/s]).

Table 4. Median tumor volumes ± standard deviation for each measurement and group.

Fisher's Linear Discriminant Analysis

The results from FLDA are also shown in Figure 6. The two groups display a statistically highly significant difference (p<0.00001, Figure 4c) between the results from the determined linear combination (FLDA(ΔVOL, ΔADC) = 0.0033×ΔVOL[%] −1.0366×ΔADC[10−3mm2/s]). The ROC curve analysis for FLDA is illustrated in Figure 5c. The AUC was 0.985 and using an optimal threshold of FLDA = 0.139 (below = therapy) a sensitivity of 91.7%, a specificity of 100%, and a diagnostic accuracy of 95.7% in differentiating between therapy and control group based on FLDA was obtained (Table 3). The AUC yielded by FLDA was significantly larger than the AUC yielded by ΔADC (p = 0.036), however, there was no significant difference compared to the AUC yielded by ΔVOL (p = 0.145).


In this study, we used MRI in an experimental colon carcinoma model to evaluate the influence of the recently FDA-approved multi-kinase inhibitor regorafenib [28] on the water diffusivity in the tumorous tissue and on tumor growth to assess the potential for non-invasive therapy monitoring using ADC and tumor volume measurements. We observed that the one-week treatment significantly increased tumor ADCs as well as significantly reduced tumor growth, however, ROC curve analyses using each parameter individually revealed a lack of accuracy (with values of about 80%) in discriminating between therapy and control group. The combination of both parameters using Fisher's linear discrimination distinctively increased the diagnostic accuracy to more than 95%, thus advocating the capability for therapy monitoring.

Tumor ADC

Diffusion-weighted MRI revealed microstructural changes in the tumorous tissue reflected by an increased water diffusivity induced by a one-week therapy with regorafenib. The significant increase in tumor ADC in the therapy group is likely due to apoptosis, which was shown to be significantly unregulated by regorafenib therapy in the same tumor cell line (HT29) [29]. A correlation between apoptosis and water diffusivity in tumorous tissue has been observed in various published studies [30], [40][42]. Zhang et al. examined mice bearing CT26 colorectal carcinoma tumors under radiotherapy using DW-MRI and histological analysis [40], which led the authors to identifying a significant positive correlation between the percentage of ADC changes and the apoptotic index (TUNEL).

The significant increase in tumor ADCs in the therapy group and more importantly the significant differences in the observed tumor ADC changes between the two groups mark DW-MRI as a potential biomarker for monitoring of molecular cancer therapy, including multi-tyrosine kinase inhibitors such as regorafenib. While Thoeny et al. have reported an initial decrease in water diffusivity in the first hours after anti-cancer therapy initiation [23], an increasing ADC in the tumorous tissue after several days of anti-cancer treatment has widely been associated with therapy response [21][23], [26], [43][45]. However, in our study the median tumor ADC in the control group also displayed a moderate increase, yet of no statistical significance. The rapid tumor growth and the significant correlation of growth and tumor ADC changes between baseline and follow-up measurement observed in the control group indicate that this increase in water diffusivity is most likely caused by progressing necrotic transformation, which is expected particularly in the untreated control group. Herneth et al. studied ADCs of squamous cell tumors implanted in mice at various tumor sizes [15], reporting that ADCs increased significantly with tumor progression and the areas with increased ADCs correlated well with histologically determined areas of necrosis.

While regorafenib seems to have a significant effect on water diffusivity, the overlap in the observed tumor ADC changes between therapy and control group leads to a less accurate discrimination and therefore to a limitation of the therapy monitoring capabilities of DW-MRI. To increase diagnostic accuracy it is therefore advisable to combine ADC measurements with additional information about tumor progression, such as tumor volume.

Tumor Volume

The tumor volume increased significantly between baseline and follow-up measurement in both groups. This strongly indicates that the Response Evaluation Criteria in Solid Tumors (RECIST) [1] based on morphologic properties of the target lesion (longest diameter), is not suitable to monitor early response of anti-angiogenic tumor therapy [2], [3]. However, the relative tumor growth was significantly reduced by the regorafenib therapy, as the control group tumors displayed a median relative tumor growth of 96.4% while therapy group tumors only grew by 33.3%. Similar results were previously published by Abou-Elkacem et al. [46], who observed that regorafenib therapy in a murine CT26 metastatic colon cancer model, amongst other anti-angiogenic and anti-metastatic effects, significantly inhibited tumor growth. The ROC curve analysis using relative tumor growth yielded a slight increase in AUC compared to using tumor ADC changes, nevertheless, tumor growth lacks diagnostic accuracy when used as classifier to distinguish between control and therapy group animals after 6 days of regorafenib therapy.

Fisher's Linear Discriminant Analysis

Fisher's linear discriminant analysis is an effective method to combine two or more classifiers in separation problems [31]. Biffar et al. demonstrated that the use of FLDA to combine ADC and T2 relaxation times of water in the vertebral bone marrow allowed for increased sensitivity and accuracy in the separation between malignant and benign lesions compared to using each classifier individually [32]. In the present study, a significant correlation between tumor ADC changes and relative tumor growth was found in the control group but not in the therapy group. While this indicates that the observed ADC changes are likely to have different physiological causes, it further promotes the application of a discriminant analysis for the purpose of increased diagnostic accuracy. Accordingly, the combined classifier resulting from FLDA of tumor ADC changes and relative tumor growth improves the discrimination between therapy and control group substantially compared to the individual use. All tumors, except for one false negative (therapy group tumor classified as control group tumor), were classified correctly using the optimal threshold determined by the ROC curve analysis. This result highlights that water diffusivity in tumorous tissue potentially reveals insight on tumor therapy response, but has to be evaluated in a meaningful way with regard to tumor morphology.


The linear combination of ADC and volume changes calculated with FLDA and also the thresholds determined with the ROC curve analyses are specific to the tumor type, the therapy and the time interval between measurements. These parameters may have to be reevaluated according to the respective settings. However, the concept of the method presented in this study to integrate morphological and functional information as complementing parameters should remain valid.

For further analysis, it may be possible to gain additional insight on the tumor physiology by investigating the histogram shape (e.g. variance or skewness) of the ADC distribution inside the VOI (Figure 7) if the voxel count of the VOI is sufficiently large (i.e. several hundred voxels per VOI). Other possible DW-MRI based evaluations not included in this study are the assessment of intravoxel incoherent motion [47], [48] or diffusional kurtosis parameters [49].

Figure 7. Exemplary histogram distributions of the voxelwise calculated ADCs inside the volume of interest for a (a) therapy and (b) control group animal.

The median tumor ADC increased in both cases (therapy: 0.72×10−3 mm2/s to 0.91×10−3 mm2/s, control: 0.73×10−3 mm2/s to 0.82×10−3 mm2/s), however, the therapy tumor grew by 36%, while the control group tumor grew by 76%.


Using quantitative DW-MRI, we found that therapy of human colon carcinoma xenografts with the multi-tyrosine kinase inhibitor regorafenib significantly increased water diffusivity in tumorous tissue after 6 days of treatment. We also observed that regorafenib significantly reduced tumor growth compared to the control group. Using either tumor ADC changes or tumor growth to distinguish between therapy and control group resulted in diagnostic accuracy of about 78% and 83%, respectively, which we consider not sufficient for an imaging biomarker. The approach to combine both parameters using Fisher's linear discriminant analysis, substantially improved the accuracy to about 96%, thus highlighting the potential of multi-parameter MRI as an imaging biomarker for non-invasive early tumor therapy monitoring.

Supporting Information

Table S1.

Voxelwise calculated ADC values for each animal and measurement.


Table S2.

Individual tumor ADC values for each animal and measurement.


Table S3.

Individual tumor volumes for each animal and measurement.


Author Contributions

Conceived and designed the experiments: CCC MFR KN. Performed the experiments: MJS CCC KN HH OD. Analyzed the data: MJS CCC KN HH OD. Contributed reagents/materials/analysis tools: MJS CCC KN HH MFR OD. Contributed to the writing of the manuscript: MJS CCC KN HH MFR OD.


  1. 1. Sohaib A (2012) RECIST rules. Cancer Imaging 12: 345–346.
  2. 2. Diederich S (2012) Imaging beyond RECIST: CT and MRI in molecular therapies. Cancer Imaging 12: 347–350.
  3. 3. Ratain MJ, Eckhardt SG (2004) Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 22: 4442–4445.
  4. 4. E. O. Stejskal JET (1965) Spin Diffusion Measurements: Spin Echoes in the Presence of a Time-Dependent Field Gradient. The Journal of Chemical Physics 42: 288–292.
  5. 5. Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, et al. (1986) MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 161: 401–407.
  6. 6. Thoeny HC, Ross BD (2010) Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging 32: 2–16.
  7. 7. Hamstra DA, Rehemtulla A, Ross BD (2007) Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 25: 4104–4109.
  8. 8. Li SP, Padhani AR (2012) Tumor response assessments with diffusion and perfusion MRI. J Magn Reson Imaging 35: 745–763.
  9. 9. Cyran CC, Paprottka PM, Eisenblatter M, Clevert DA, Rist C, et al. (2014) Visualization, imaging and new preclinical diagnostics in radiation oncology. Radiat Oncol 9: 3.
  10. 10. Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, et al. (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11: 102–125.
  11. 11. Patterson DM, Padhani AR, Collins DJ (2008) Technology insight: water diffusion MRI–a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol 5: 220–233.
  12. 12. Manenti G, Di Roma M, Mancino S, Bartolucci DA, Palmieri G, et al. (2008) Malignant renal neoplasms: correlation between ADC values and cellularity in diffusion weighted magnetic resonance imaging at 3 T. Radiol Med 113: 199–213.
  13. 13. Humphries PD, Sebire NJ, Siegel MJ, Olsen OE (2007) Tumors in pediatric patients at diffusion-weighted MR imaging: apparent diffusion coefficient and tumor cellularity. Radiology 245: 848–854.
  14. 14. Zelhof B, Pickles M, Liney G, Gibbs P, Rodrigues G, et al. (2009) Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU Int 103: 883–888.
  15. 15. Herneth AM, Guccione S, Bednarski M (2003) Apparent diffusion coefficient: a quantitative parameter for in vivo tumor characterization. Eur J Radiol 45: 208–213.
  16. 16. Sumi M, Sakihama N, Sumi T, Morikawa M, Uetani M, et al. (2003) Discrimination of metastatic cervical lymph nodes with diffusion-weighted MR imaging in patients with head and neck cancer. AJNR Am J Neuroradiol 24: 1627–1634.
  17. 17. Biffar A, Baur-Melnyk A, Schmidt GP, Reiser MF, Dietrich O (2011) Quantitative analysis of the diffusion-weighted steady-state free precession signal in vertebral bone marrow lesions. Invest Radiol 46: 601–609.
  18. 18. Dzik-Jurasz A, Domenig C, George M, Wolber J, Padhani A, et al. (2002) Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 360: 307–308.
  19. 19. DeVries AF, Kremser C, Hein PA, Griebel J, Krezcy A, et al. (2003) Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys 56: 958–965.
  20. 20. Koh DM, Scurr E, Collins D, Kanber B, Norman A, et al. (2007) Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am J Roentgenol 188: 1001–1008.
  21. 21. Cui Y, Zhang XP, Sun YS, Tang L, Shen L (2008) Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 248: 894–900.
  22. 22. Theilmann RJ, Borders R, Trouard TP, Xia G, Outwater E, et al. (2004) Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 6: 831–837.
  23. 23. Thoeny HC, De Keyzer F, Chen F, Vandecaveye V, Verbeken EK, et al. (2005) Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration. Neoplasia 7: 779–787.
  24. 24. Roe K, Kakar M, Seierstad T, Ree AH, Olsen DR (2011) Early prediction of response to radiotherapy and androgen-deprivation therapy in prostate cancer by repeated functional MRI: a preclinical study. Radiat Oncol 6: 65.
  25. 25. Wybranski C, Zeile M, Lowenthal D, Fischbach F, Pech M, et al. (2011) Value of diffusion weighted MR imaging as an early surrogate parameter for evaluation of tumor response to high-dose-rate brachytherapy of colorectal liver metastases. Radiat Oncol 6: 43.
  26. 26. Halappa VG, Bonekamp S, Corona-Villalobos CP, Li Z, Mensa M, et al. (2012) Intrahepatic cholangiocarcinoma treated with local-regional therapy: quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response. Radiology 264: 285–294.
  27. 27. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, et al. (2011) Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129: 245–255.
  28. 28. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, et al. (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381: 303–312.
  29. 29. Cyran CC, Kazmierczak PM, Hirner H, Moser M, Ingrisch M, et al. (2013) Regorafenib effects on human colon carcinoma xenografts monitored by dynamic contrast-enhanced computed tomography with immunohistochemical validation. PLoS One 8: e76009.
  30. 30. Liimatainen T, Hakumaki JM, Kauppinen RA, Ala-Korpela M (2009) Monitoring of gliomas in vivo by diffusion MRI and (1)H MRS during gene therapy-induced apoptosis: interrelationships between water diffusion and mobile lipids. NMR Biomed 22: 272–279.
  31. 31. Fisher RA (1936) The Use of Multiple Measurements in Taxonomic Problems. Annals of Eugenics 7: 179–188.
  32. 32. Biffar A, Baur-Melnyk A, Schmidt GP, Reiser MF, Dietrich O (2010) Multiparameter MRI assessment of normal-appearing and diseased vertebral bone marrow. Eur Radiol 20: 2679–2689.
  33. 33. Morelli JN, Runge VM, Feiweier T, Kirsch JE, Williams KW, et al. (2010) Evaluation of a modified Stejskal-Tanner diffusion encoding scheme, permitting a marked reduction in TE, in diffusion-weighted imaging of stroke patients at 3 T. Invest Radiol 45: 29–35.
  34. 34. Sourbron S, Biffar A, Ingrisch M, Fierens Y, Luypaert R (2009) PMI: platform for research in medical imaging. Magn Reson Mater Phy 22: 539.
  35. 35. R Development Core Team (2008) R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
  36. 36. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, et al. (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12: 77.
  37. 37. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44: 837–845.
  38. 38. Slawski M, Boulesteix A-L, Bernau C (2009) CMA: Synthesis of microarray-based classification.
  39. 39. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.
  40. 40. Zhang XY, Sun YS, Tang L, Xue WC, Zhang XP (2011) Correlation of diffusion-weighted imaging data with apoptotic and proliferation indexes in CT26 colorectal tumor homografts in balb/c mouse. J Magn Reson Imaging 33: 1171–1176.
  41. 41. Kim H, Morgan DE, Buchsbaum DJ, Zeng H, Grizzle WE, et al. (2008) Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. Cancer Res 68: 8369–8376.
  42. 42. Huang MQ, Pickup S, Nelson DS, Qiao H, Xu HN, et al. (2008) Monitoring response to chemotherapy of non-Hodgkin's lymphoma xenografts by T(2)-weighted and diffusion-weighted MRI. NMR Biomed 21: 1021–1029.
  43. 43. Pickles MD, Gibbs P, Lowry M, Turnbull LW (2006) Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 24: 843–847.
  44. 44. Zhai G, Kim H, Sarver D, Samuel S, Whitworth L, et al.. (2013) Early therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and H MR spectroscopy. J Magn Reson Imaging.
  45. 45. Juge L, Doan BT, Seguin J, Albuquerque M, Larrat B, et al. (2012) Colon tumor growth and antivascular treatment in mice: complementary assessment with MR elastography and diffusion-weighted MR imaging. Radiology 264: 436–444.
  46. 46. Abou-Elkacem L, Arns S, Brix G, Gremse F, Zopf D, et al. (2013) Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther 12: 1322–1331.
  47. 47. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, et al. (1988) Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 168: 497–505.
  48. 48. Ganten MK, Schuessler M, Bauerle T, Muenter M, Schlemmer HP, et al. (2013) The role of perfusion effects in monitoring of chemoradiotherapy of rectal carcinoma using diffusion-weighted imaging. Cancer Imaging 13: 548–556.
  49. 49. Bauer WR, Ziener CH, Jakob PM (2005) Non-Gaussian spin dephasing. Physical Review A 71.